Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Assets (2020 - 2026)

Immuneering's Assets history spans 7 years, with the latest figure at $214.8 million for Q1 2026.

  • On a quarterly basis, Assets rose 323.84% to $214.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $214.8 million, a 323.84% increase, with the full-year FY2025 number at $232.0 million, up 340.08% from a year prior.
  • Assets came in at $214.8 million for Q1 2026, down from $232.0 million in the prior quarter.
  • The five-year high for Assets was $241.1 million in Q3 2025, with the low at $40.1 million in Q2 2025.
  • Historically, Assets has averaged $121.4 million across 5 years, with a median of $113.9 million in 2023.
  • Biggest five-year swings in Assets: crashed 48.61% in 2024 and later soared 340.08% in 2025.
  • Year by year, Assets stood at $122.4 million in 2022, then fell by 16.17% to $102.6 million in 2023, then plummeted by 48.61% to $52.7 million in 2024, then surged by 340.08% to $232.0 million in 2025, then decreased by 7.4% to $214.8 million in 2026.
  • Business Quant data shows Assets for IMRX at $214.8 million in Q1 2026, $232.0 million in Q4 2025, and $241.1 million in Q3 2025.